# BelaRd (NCT04808037)

> Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

No report yet. It can be ordered.

- Drugs tested: belantamab mafodotin plus lenalidomide plus dexamethasone
- Indication: transplant-ineligible newly diagnosed multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04808037
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hellenic Society of Hematology
- Conditions: Multiple Myeloma
- Interventions: Belantamab mafodotin
- Enrollment: 66
- Primary outcome: Number of participants with dose-limiting toxicities (DLTs) in each of the cohorts 1-3
- Primary outcome: Overall Response rate as per IMWG by Investigator Assessment, defined as the percentage of participants with a confirmed PR, VGPR, CR or sCR
- Primary outcome: Number of participants with adverse events (AEs) and serious adverse events (SAEs) in each of the cohorts 1-3
- Primary outcome: Number of participants with adverse events (AEs) and serious adverse events (SAEs) in patients receiving the Recommended Phase 2 Dose

## Indexed commentary on BelaRd so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X
- 1 YouTube video
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=belard-nct04808037